<DOC>
	<DOCNO>NCT02695563</DOCNO>
	<brief_summary>The aim study evaluate effect vaginal lactoferrin administration amniotic fluid PGE2 level MMP-TIMP system woman undergo genetic amniocentesis . Two group patient prospectively enrol : treat lactoferrin treat vaginal lactoferrin 4 hour prior mid-trimester genetic amniocentesis .</brief_summary>
	<brief_title>Effects Vaginal Lactoferrin Administration Prior Genetic Amniocentesis Inflammatory Mediators</brief_title>
	<detailed_description>Pregnant woman undergo genetic amniocentesis within 16th-18th gestational week enrol Obstetric Unit , University Ferrara . The selected patient randomly assign receive vaginal compound contain 300 mg lactoferrin 4 hour amniocentesis untreated ( control ) . Amniotic fluid sample obtain transabdominal amniocentesis sample required clinical purpose centrifuge remove particulate material supernatant aliquoted stored -80Â°C assay .</detailed_description>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>singleton gestation maternal age indication fetal karyotyping consumption drug interfere immune system previous miscarriage pregnancy risk maternal fetal disease lactose intolerance</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Amniocentesis</keyword>
</DOC>